ArticleJTO clinical and research reports2024

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations.

Tia Cheunkarndee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.